Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded DMRA from “sell” to “hold,” while the broader analyst consensus remains “Buy” with a $46.50 price target. Ratings include three Strong Buys, seven Buys, one Hold, and one Sell.
• The stock opened at $21.08, below its 50-day and 200-day moving averages of $26.55 and $25.92, respectively, and has traded between $4.95 and $38.33 over the past year.
• CEO Jennifer Jarrett purchased 12,500 shares for approximately $252,875, while institutional investors—including Braidwell LP and Seven Fleet Capital—also established positions; institutions collectively own 14.20% of the stock.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Sunday, Wall Street Zen reports.

A number of other equities analysts also recently commented on DMRA. Wedbush reissued an "outperform" rating and issued a $40.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, September 29th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Guggenheim increased their price target on Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the company a "buy" rating in a report on Friday, September 25th. Jefferies Financial Group began coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They issued a "buy" rating and a $50.00 price target for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $46.50.

Damora Therapeutics, Inc. Common Stock Stock Performance

DMRA opened at $21.08 on Friday. The firm has a 50 day moving average price of $26.55 and a 200 day moving average price of $25.92. The company has a market cap of $1.30 billion, a PE ratio of -6.26 and a beta of 1.43. Damora Therapeutics, Inc. Common Stock has a 1 year low of $4.95 and a 1 year high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.06. On average, sell-side analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current year.

Insider Transactions at Damora Therapeutics, Inc. Common Stock

In other news, CEO Jennifer Jarrett acquired 12,500 shares of the company's stock in a transaction dated Friday, September 25th. The shares were bought at an average price of $20.23 per share, for a total transaction of $252,875.00. Following the completion of the purchase, the chief executive officer directly owned 512,500 shares of the company's stock, valued at approximately $10,367,875. This trade represents a 2.50% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Arizona State Retirement System purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth $260,000. Squarepoint Ops LLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the 2nd quarter worth $303,000. Seven Fleet Capital Management LP purchased a new position in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $7,398,000. Finally, Braidwell LP purchased a new position in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $42,146,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.